How India Exports Neosporin to the World

In the United States, Neosporin is classified as an over-the-counter (OTC) medication, allowing consumers to purchase it without a prescription. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of Neosporin's active ingredients, indicating a competitive market with several manufacturers. Notably, the FDA approved an ANDA for a generic version of Neosporin in March 2025, reflecting ongoing interest in this product category.

The substantial number of Indian exporters (99) involved in shipping Neosporin to the U.S. underscores India's significant role in supplying this product. However, exporters must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and accurate labeling standards, to ensure market access and maintain product integrity.

In the European Union, Neosporin's active ingredients require marketing authorization from the European Medicines Agency (EMA) before commercialization. The EMA mandates adherence to EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval process, necessitating compliance with UK-specific GMP standards.

As of March 2026, there have been no recent EMA or MHRA actions specifically concerning Neosporin, indicating stable regulatory standing within these jurisdictions.

The World Health Organization (WHO) includes the combination of neomycin and bacitracin on its Model List of Essential Medicines, recognizing their importance in basic healthcare systems. This inclusion underscores the global significance of these antibiotics in treating bacterial infections. Additionally, Neosporin's active ingredients are standardized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality benchmarks across different regions.

In India, Neosporin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for Neosporin, allowing market-driven pricing. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The original patents for Neosporin's formulation have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, including Indian exporters, who now supply Neosporin to a diverse range of countries.

In June 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of neomycin and bacitracin, highlighting their continued relevance in global healthcare. In September 2025, the FDA approved a new generic version of Neosporin, further increasing market competition. Additionally, in December 2025, the Indian Ministry of Health and Family Welfare introduced revised GMP guidelines, aligning more closely with international standards, impacting manufacturers of Neosporin and similar products.

These developments reflect the dynamic nature of the pharmaceutical industry, emphasizing the need for exporters to stay informed about regulatory changes and market trends to maintain compliance and competitiveness.

The production of Neosporin relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), many of which are sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used for U.S.-approved APIs are solely sourced from China, while 16% come from India. This heavy reliance on Chinese suppliers poses a significant risk, as any disruption in China's production capabilities—due to environmental regulations, trade restrictions, or geopolitical tensions—could severely impact the availability of essential raw materials for Neosporin manufacturing.

Furthermore, the complex and hazardous nature of KSM production makes it challenging to relocate these manufacturing processes to other countries. China's dominance in this sector means that even if API production occurs in India, the dependency on Chinese KSMs remains a critical vulnerability in the supply chain.

Our proprietary trade data indicates that the top five Indian exporters of Neosporin account for 43.5% of total exports, with PARAGON DIAGNOSTICS leading at a 10.3% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could impact a significant portion of Neosporin exports.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing of critical APIs and reduce import dependency. As of September 2025, the scheme has led to the creation of manufacturing capacities for 26 KSMs and APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions and conflicts, which can lead to delays and increased transportation costs for pharmaceutical exports. Additionally, ongoing U.S.-China trade tensions have the potential to disrupt the supply of KSMs and APIs sourced from China, further complicating the supply chain for Neosporin.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various pharmaceuticals in recent years, underscoring the fragility of global supply chains. While specific alerts for Neosporin have not been reported, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects on others.

• Diversify Supplier Base: Identify and qualify alternative suppliers for KSMs and APIs to reduce dependency on single-source suppliers, particularly those in China.

• Enhance Domestic Production: Leverage government initiatives like the PLI Scheme to strengthen domestic manufacturing capabilities for critical raw materials.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact shipping routes and raw material availability, enabling proactive risk management.

• Strengthen Supplier Relationships: Develop strategic partnerships with key suppliers to ensure priority access to materials during periods of high demand or disruption.

• Implement Supply Chain Transparency: Utilize advanced tracking and reporting systems to gain real-time visibility into the supply chain, allowing for swift responses to potential disruptions.

RISK_LEVEL: MEDIUM